miR-155对前列腺癌放射治疗的增敏作用

摘要
图/表
参考文献
相关文章 (14)

全文: PDF (674 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨miR-155在前列腺癌放射治疗(简称放疗)中的增敏作用。方法转染anti-miR-155,抑制前列腺癌DU145和PC-3细胞中miR-155水平,联合应用放射治1疗,通过观察DU145和PC-3细胞的存活率、黏附率,以及前列腺癌细胞的凋亡率,并观察Caspase-3和Caspase-9表达水平和活性的变化。结果与对照组相比,DU145和PC-3细胞经放射或anti-miR-155单独处理后,细胞存活率(放射组分别为25.6%±2.0%和21.6±1.0%;anti-miR-155处理组分别为20.5%±1.0%和15.5%±1.0%)和黏附率(放射组分别为0.8%±0.1%和0.7%±0.1%;anti-miR-155处理组分别为0.7%±0.1%和0.6%±0.1%)均显著降低(P<0.01);前列腺癌细胞凋亡率增高(放射组分别为3.3%±0.3%和4.2%±0.3%;anti-miR-155处理组分别为4.1%±0.1%和3.9%±0.2%);Caspase-3和Caspase-9表达水平和活性均提高(P<0.01);联合组的细胞存活率(分别为10.1%±0.5%和6.1%±0.5%)和黏附率(分别为0.4%±0.1%和0.4%±0.1%)低于单独处理组(P<0.01,n=6),细胞凋亡率(分别为6.9%±0.4%和6.8%±0.3%),Caspase-3和Caspase-9表达水平和活性等均高于单独处理组(P<0.01)。结论抑制miR-155可增加人前列腺癌的放疗敏感性,提高放射线对人前列腺癌细胞的治疗效果,其机制可能与Caspase-3和Caspase-9参与细胞凋亡的途径相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	董青川
	张治国
	程继
	王志刚
	赵华才
	赵文彩
	张海艳
	程永毅

关键词 ： miR-155, 前列腺癌, 放疗增敏, Caspase-3, Caspase-9

Abstract：Objective To explore the effects of miR-155 on radiosensitivity enhancement of prostate cancer in vitro.Methods Cell viability and adhesion of DU145 and PC-3 cells were evaluated after anti-miR-155 transfection combined with irradiation therapy. Flow cytometry was performed to evaluate the cell apoptosis. The expression and activity of Caspase-3 and Caspase-9 were also observed after the above treatment.Results The results evidenced that cell viability(25.6%±2.0% and 21.6±1.0% in irradiated group;20.5%±1.0% and 15.5%±1.0% in anti-miR-155 transfected group) and adhesion of DU145 and PC-3 cells(0.8%±0.1% and 0.7%±0.1% in irradiated group;0.7%±0.1% and 0.6%±0.1% in anti-miR-155 transfected group) were inhibited obviously after anti-miR-155 transfection. The apoptosis rate(3.3%±0.3% and 4.2%±0.3% in irradiated group;4.1%±0.1% and 3.9%±0.2% in anti-miR-155 transfected group), Caspase-3 and Caspase-9 expression and activity were enhanced obviously compared with the control group(P<0.01).After combinative treatment, cell viability (10.1%±0.5% in irradiated group and 6.1%±0.5% in anti-miR-155 transfected group) and adhesion (0.4%±0.1% in irradiated group and 0.4%±0.1% in anti-miR-155 transfected group)decreased significantly(P<0.01,n=6).The apoptosis rate(6.9%±0.4% in irradiated group;6.8%±0.3% in anti-miR-155 transfected group) and the expression of Caspase-3 and Caspase-9 were also higher than the signal treated group(P<0.01).Conclusions Our results suggested that miR-155 can increase the radiosensitivity of DU145 and PC-3 cells and increase the efficiency of radiotherapy of γ-ray irradiation on prostate cancer in vitro.

Key words： miR-155 prostate cancer radiosensitivity Caspase-3 Caspase-9

收稿日期: 2016-06-20

ZTFLH:

R737.25

基金资助:陕西省科技攻关项目(2011JQ4017)

通讯作者: 程永毅,E-mail:dongqc168@163.com

作者简介: 董青川,博士,主治医师。

引用本文:

董青川,张治国,程继,王志刚,赵华才,赵文彩,张海艳,程永毅. miR-155对前列腺癌放射治疗的增敏作用[J]. 武警医学, 2017, 28(1): 60-63. DONG Qingchuan, ZHANG Zhiguo,CHENG Ji, WANG Zhigang, ZHAO Huacai, ZHAO Wencai, ZHANG Haiyan, and CHENG Yongyi. Effect of miR-155 on radiosensitivity enhancement of prostate cancer in vitro. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(1): 60-63.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2017/V28/I1/60

[1]	Brody H. Prostate cancer [J]. Nature, 2015, 528(7582): S117.
[2]	Xin L. Cells of origin for cancer: an updated view from prostate cancer [J]. Oncogene, 2013, 32(32): 3655-3663.
[3]	Jerónimo C, Bastian P J, Bjartell A, et al. Epigenetics in prostate cancer: biologic and clinical relevance [J]. Eur Urol, 2011, 60(4): 753-766.
[4]	Bertoli G, Cava C, Castiglioni I. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer [J]. Int J Mol Sci, 2016, 17(3): 245-251.
[5]	Tutar Y. miRNA and cancer; computational and experimental approaches [J]. Curr Pharm Biotechnol, 2014, 15(5): 429-436.
[6]	Cai Z K, Chen Q, Chen Y B, et al. microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7 [J]. Mol Med Rep, 2015, 11(1): 533-538.
[7]	Ji H, Li Y, Jiang F, et al. Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer [J]. Cancer Sci, 2014, 105(12):1541-1549.
[8]	Babar I A, Czochor J, Steinmetz A, et al. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells [J]. Cancer Biol Ther, 2011, 12(10): 908-914.
[9]	Challagundla K B, Wise P M, Neviani P, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy [J]. J Natl Cancer Inst, 2015, 107(7):1093-1098.
[10]	Barbieri C E, Demichelis F, Rubin M A. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity [J]. Histopathology, 2012, 60(1):187-198.
[11]	Chang L, Graham P H, Ni J, et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance [J]. Crit Rev Oncol Hematol, 2015, 96(3): 507-517.
[12]	Kiliccioglu I, Konac E, Varol N, et al. Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines [J]. Genet Mol Res, 2014, 13(2): 3721-3731.
[13]	Das T P, Suman S, Alatassi H, et al. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer [J]. Cell Death Dis, 2016, 7: e2111.
[14]	Jain A, Jain S, Jain R, et al. Coated chitosan nanoparticles encapsulating caspase 3 activator for effective treatment of colorectral cancer [J]. Drug Deliv Transl Res, 2015, 5(6): 596-610.
[15]	Yan J, Ma C, Cheng J, et al. HAX-1 inhibits apoptosis in prostate cancer through the suppression of caspase-9 activation [J]. Oncol Rep, 2015, 34(5): 2776-2781.
[16]	Lu T, Stark G R. NF-κB: regulation by methylation [J]. Cancer Res, 2015, 75(18): 3692-3695.
[17]	Turturro F. Constitutive NF- κ B activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma [J]. Biomed Res Int, 2015,2015:484537.